Kashappa-Goud H Desai
Overview
Explore the profile of Kashappa-Goud H Desai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
168
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Self-encapsulating Poly(lactic-co-glycolic acid) (PLGA) Microspheres for Intranasal Vaccine Delivery
Bailey B, Desai K, Ochyl L, Ciotti S, Moon J, Schwendeman S
Mol Pharm
. 2017 Jul;
14(9):3228-3237.
PMID: 28726424
Herein we describe a formulation of self-encapsulating poly(lactic-co-glycolic acid) (PLGA) microspheres for vaccine delivery. Self-healing encapsulation is a novel encapsulation method developed by our group that enables the aqueous loading...
2.
Hansen K, Kim G, Desai K, Patel H, Olsen K, Curtis-Fisk J, et al.
Mol Pharm
. 2015 Jun;
12(8):2732-41.
PMID: 26097994
The feasibility of various cellulose polymer derivatives, including methylcellulose (MC), hydroxypropyl methylcellulose (HPMC), sodium-carboxymethylcellulose (sodium-CMC), and cationic-hydroxyethylcellulose (cationic-HEC), for use as an excipient to enhance drug delivery in nasal spray...
3.
Sophocleous A, Desai K, Mazzara J, Tong L, Cheng J, Olsen K, et al.
J Control Release
. 2013 Sep;
172(3):662-70.
PMID: 24021356
An important poorly understood phenomenon in controlled-release depots involves the strong interaction between common cationic peptides and low Mw free acid end-group poly(lactic-co-glycolic acids) (PLGAs) used to achieve continuous peptide...
4.
Desai K, Kadous S, Schwendeman S
Pharm Res
. 2013 Mar;
30(7):1768-78.
PMID: 23515830
Purpose: To investigate the effect of γ-irradiation of poly(lactic-co-glycolic acid) (PLGA)/Al(OH)₃/0 or 5 wt% diethyl phthalate (DEP) microspheres for active self-healing encapsulation of vaccine antigens. Methods: Microspheres were irradiated with...
5.
Desai K, Schwendeman S
J Control Release
. 2012 Oct;
165(1):62-74.
PMID: 23103983
Herein, we describe the detailed development of a simple and effective method to microencapsulate vaccine antigens in poly(lactic-co-glycolic acid) (PLGA) by simple mixing of preformed active self-microencapsulating (SM) PLGA microspheres...
6.
Reinhold S, Desai K, Zhang L, Olsen K, Schwendeman S
Angew Chem Int Ed Engl
. 2012 Sep;
51(43):10800-3.
PMID: 23011773
No abstract available.
7.
Holpuch A, Phelps M, Desai K, Chen W, Koutras G, Han B, et al.
Carcinogenesis
. 2012 Mar;
33(5):1098-105.
PMID: 22427354
Systemic delivery of fenretinide in oral cancer chemoprevention trials has been largely unsuccessful due to dose-limiting toxicities and subtherapeutic intraoral drug levels. Local drug delivery, however, provides site-specific therapeutically relevant...
8.
Wu X, Desai K, Mallery S, Holpuch A, Phelps M, Schwendeman S
Mol Pharm
. 2012 Jan;
9(4):937-45.
PMID: 22280430
The objective of this study was to enhance oral mucosal permeation of fenretinide by coincorporation of propylene glycol (PG) and menthol in fenretinide/Eudragit RL PO mucoadhesive patches. Fenretinide is an...
9.
Holpuch A, Desai K, Schwendeman S, Mallery S
J Carcinog
. 2011 Oct;
10:23.
PMID: 22013393
Due to its characterized progression from recognized premalignant oral epithelial changes (i.e., oral epithelial dysplasia) to invasive cancer, oral squamous cell carcinoma represents an optimal disease for chemopreventive intervention prior...
10.
Desai K, Mallery S, Holpuch A, Schwendeman S
Pharm Res
. 2011 Jun;
28(10):2599-609.
PMID: 21674264
Purpose: To develop fenretinide oral mucoadhesive patch formulations and evaluate their in vitro and in vivo release performance for future site-specific chemoprevention of oral cancer. Methods: Solubilization of fenretinide in...